INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 319 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $48,919,681 | -30.4% | 1,547,112 | -10.2% | 0.02% | -27.6% |
| Q2 2023 | $70,254,846 | +6.8% | 1,722,777 | -2.4% | 0.03% | +3.6% |
| Q1 2023 | $65,778,867 | +11.6% | 1,764,928 | +4.5% | 0.03% | +3.7% |
| Q4 2022 | $58,954,401 | -25.9% | 1,689,722 | +18.8% | 0.03% | -30.8% |
| Q3 2022 | $79,586,000 | -9.8% | 1,422,201 | -16.6% | 0.04% | -2.5% |
| Q2 2022 | $88,233,000 | -30.5% | 1,704,651 | -2.5% | 0.04% | -18.4% |
| Q1 2022 | $127,004,000 | -26.6% | 1,747,681 | +19.5% | 0.05% | -19.7% |
| Q4 2021 | $172,945,000 | +4.2% | 1,462,660 | +18.3% | 0.06% | -6.2% |
| Q3 2021 | $165,931,000 | -15.3% | 1,236,904 | +2.3% | 0.06% | -17.7% |
| Q2 2021 | $195,825,000 | +38.8% | 1,209,468 | -31.2% | 0.08% | +27.4% |
| Q1 2021 | $141,073,000 | +4076.2% | 1,757,812 | +2730.6% | 0.06% | +3000.0% |
| Q4 2020 | $3,378,000 | +175.8% | 62,100 | +0.8% | 0.00% | +100.0% |
| Q3 2020 | $1,225,000 | -7.3% | 61,600 | -2.1% | 0.00% | 0.0% |
| Q2 2020 | $1,322,000 | +101.5% | 62,900 | +17.4% | 0.00% | – |
| Q1 2020 | $656,000 | -16.5% | 53,600 | 0.0% | 0.00% | – |
| Q4 2019 | $786,000 | +9.8% | 53,600 | 0.0% | 0.00% | – |
| Q3 2019 | $716,000 | -18.4% | 53,600 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $877,000 | -4.2% | 53,600 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $915,000 | +13.9% | 53,600 | -8.8% | 0.00% | 0.0% |
| Q4 2018 | $803,000 | -52.3% | 58,800 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $1,683,000 | +4.6% | 58,800 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,609,000 | +225.7% | 58,800 | +151.3% | 0.00% | – |
| Q1 2018 | $494,000 | -9.2% | 23,400 | -17.3% | 0.00% | – |
| Q4 2017 | $544,000 | -19.2% | 28,300 | +4.4% | 0.00% | -100.0% |
| Q3 2017 | $673,000 | +38.5% | 27,100 | -10.9% | 0.00% | – |
| Q2 2017 | $486,000 | +33.5% | 30,400 | +17.8% | 0.00% | – |
| Q1 2017 | $364,000 | +7.7% | 25,800 | 0.0% | 0.00% | – |
| Q4 2016 | $338,000 | -13.3% | 25,800 | +12.7% | 0.00% | – |
| Q3 2016 | $390,000 | -9.9% | 22,900 | +12.8% | 0.00% | – |
| Q2 2016 | $433,000 | – | 20,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 572,950 | $19,990,226 | 5.79% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $39,952,225 | 5.34% |
| MPM BioImpact LLC | 455,238 | $15,883,254 | 4.12% |
| ARK Investment Management | 9,420,782 | $328,691,084 | 2.85% |
| Atlas Venture Associates IX, LLC | 10,000 | $348,900 | 1.74% |
| Ghisallo Capital Management LLC | 250,000 | $8,722,500 | 1.55% |
| Nikko Asset Management Americas, Inc. | 2,976,002 | $103,743,430 | 1.49% |
| Prosight Management, LP | 72,116 | $2,516,127 | 1.37% |
| Rokos Capital Management LLP | 826,063 | $28,391,785 | 1.24% |
| Elmwood Wealth Management, Inc. | 67,899 | $2,368,996 | 1.18% |